Neuren Pharmaceuticals Limited · ASX:NEU

Neuren Pharmaceuticals — Corporate Update (August 2018)

8 slides from Neuren Pharmaceuticals's corporate update, Aug 7, 2018

  1. Slide 1: Investor Update

    Investor Update 7 August 2018 1

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to

  3. Slide 3: Introduction

    Introduction “Neuren is in a far stronger position following the partnership with ACADIA Pharmaceuticals announced today. It makes a very significant and immediate difference in our ability to complete the development of trofinetide for patients in North America and around the world. Importantly, Ne

  4. Slide 4: Strong position following ACADIA partnership

    Strong position following ACADIA partnership  Capabilities and funding secured to get trofinetide to market  Exclusive license to ACADIA for North America, Neuren retains all rights outside North America  Neuren to receive up to US$465 million plus royalties plus share of value of Rare Pediatric

  5. Slide 5: Key features of ACADIA partnership

    Key features of ACADIA partnership  ACADIA granted exclusive license for North America, Neuren retains all rights outside North America  Neuren receives:  Milestone payments up to US$465 million  Escalating tiered double-digit percentage royalties on net sales of trofinetide in North America  O

  6. Slide 6: Key features of ACADIA partnership

    Key features of ACADIA partnership  ACADIA provides the strong capabilities and resources that are necessary to fund and execute Phase 3 development in the US  ACADIA team has proven record developing and commercializing CNS disorders in the US that have no approved therapies and high unmet need 

  7. Slide 7: Advancing NNZ-2591

    Advancing NNZ-2591  Demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X syndrome, memory impairment and multiple sclerosis  Funds now available to accelerate CMC and pre-clinical development required prior to clinica

  8. Slide 8: Neuren's near-term priorities

    Neuren’s near-term priorities  Actively support ACADIA in development of trofinetide in North America  US Phase 3 program in Rett syndrome  Fragile X syndrome development plan  Advance Neuren’s strategy to develop and commercialise trofinetide outside North America  Engage with regulatory autho

Neuren Pharmaceuticals — Corporate Update (August 2018) on 6ix